From: Potential roles and prognostic significance of exosomes in cancer drug resistance
 | Drug/Compound | Mechanism | Ref. |
---|---|---|---|
Inhibition of exosome biogenesis and secretion | GW4869 | Targeting neutral sphingomyelinase 2 | [29] |
Manumycin | Inhibition of Ras/Raf/MEK/ERK1/2 signaling pathway | [99] | |
Indomethacin | Blocking the expression of ABCA-3 | [33] | |
Ketotifen | Unknown | [100] | |
Chloramidine and bisindolylmaleimide-I | Unknown | [101] | |
Lansoprazole (proton pump inhibitor) | Decreasing microenvironmental acidity | [96] | |
Inhibition of exosome internalization | Heparin | Inhibition of HSPG mediated endocytosis | [104] |
Cytochalasin D | Inhibition of actin polymerization | [105] | |
Dynasore | Inhibition of the GTPase activity of dynamin | [106] | |
Chlorpromazine | Inhibition of clathrin-dependent endocytosis | [107] | |
Methyl-β-cyclodextrin | Remove cholesterol from the cell membrane | [108] | |
Nystatin and Simvastatin* | Inhibition of the lipid raft -mediated endocytosis pathway/*Inhibitor of HMG-CoA | [109] | |
Filipin III | Inhibitor of lipid raft dependent and caveolar endocytosis | [88] |